Comera Life Sciences Holdings, Inc. (CMRA)

Market Cap	30.50M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	22.27M
EPS (ttm)	-6.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	238,710
Open	1.42
Previous Close	1.41
Day's Range	1.31 - 1.52
52-Week Range	1.11 - 15.30
Beta	0.98
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 9, 2023

About CMRA

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Scien...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mr. Jeffrey S. Hackman
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: CMRA